COMMUNIQUÉS West-GlobeNewswire

Selecta Biosciences to Present at Canaccord Genuity’s 39th Annual Growth Conference on August 7, 2019
31/07/2019
WATERTOWN, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune [...]
CB2 Insights Adds Former Johnson & Johnson Executive as Director
31/07/2019
TORONTO, July 31, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the [...]
Kaleido Biosciences to Present at the 39th Annual Canaccord Genuity Growth Conference
31/07/2019
LEXINGTON, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to [...]
Tauriga Sciences Inc. to Integrate QR Codes into Future Product Package Design(s)
31/07/2019
New York, NY, July 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG ) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, [...]
Strongbridge Biopharma plc Reports Second Quarter 2019 Financial Results and Provides Corporate Update
31/07/2019
~ KEVEYIS ® (dichlorphenamide) Second Quarter 2019 Revenue of $6.1 Million ~ ~ Company on Track to Meet Full-Year 2019 KEVEYIS ® Revenue Guidance of $18 to $20 Million ~ ~ Enrollment in Phase 3 LOGICS Study for RECORLEV [...]
Harrow Health Announces Launch of Mayfield Pharmaceuticals
31/07/2019
Experienced Team to Seek FDA-Approval for Three Branded Women’s Health Drug Candidates NASHVILLE, Tenn., July 31, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), today announced it has filed a Form 8-K with [...]
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
31/07/2019
Preclinical Studies Show CK-3773274 Produces Exposure Related Effects on Cardiac Contractility in Healthy Animals and Mouse Models of Hypertrophic Cardiomyopathy and Support Therapeutic Hypothesis for Onset of Action [...]
Vaccinex Announces $13.8 Million Private Placement
31/07/2019
Participants include a syndicate of existing and new shareholders ROCHESTER, N.Y., July 31, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational [...]
Aravive Reports Preliminary Results of AVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial
31/07/2019
AVB-500 in combination with standard of care demonstrates early proof of concept for anti-tumor activity in platinum-resistant ovarian cancer Aravive to expand enrollment in Phase 1b Trial of AVB-500 in platinum- [...]
Clearside Biomedical Announces Multiple Oral Presentations Delivered at the American Society of Retinal Specialists (ASRS) Annual Meeting
31/07/2019
- Suprachoroidal Space injections can be easily conducted in physicians’ offices as a potentially useful method of ocular distribution of drug to target back of the eye diseases - ALPHARETTA, Ga., July 31, 2019 (GLOBE [...]
CRISPR Therapeutics to Present at Upcoming Investor Conferences
31/07/2019
ZUG, Switzerland and CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, [...]
Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies
31/07/2019
VANCOUVER, British Columbia, July 31, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development [...]
ASLAN Pharmaceuticals to Present New Data on Varlitinib at European Society for Medical Oncology Congress
31/07/2019
SINGAPORE, July 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on varlitinib has been [...]
New number of shares and votes in Oasmia Pharmaceutical AB (publ)
31/07/2019
The number of shares and votes in Oasmia Pharmaceutical AB (publ) has increased as a result of Oasmia's largest shareholder Arwidsro's utilization of a total of 24.2 million warrants in accordance with the previously [...]
Change in number of shares and votes in Saniona AB (publ)
31/07/2019
PRESS RELEASE July 31, 2019 During July, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to the completed rights issue. As of July 31, 2019, the registered number of shares [...]
Wellington Partners raises EUR 210 million life science fund
31/07/2019
News Wellington Partners raises EUR 210 million life science fund Fifth life science fund closes well above initial target range of EUR 120-150 million Fund to focus on breakthrough innovation with the potential to [...]
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
31/07/2019
Basel, 31 July 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to [...]
EssilorLuxottica: EssilorLuxottica to acquire HAL's 76.72% interest in GrandVision and launch a mandatory public offer for the remaining shares upon completion of the transaction
31/07/2019
EssilorLuxottica to acquire HAL's 76.72% interest in GrandVision and launch a mandatory public offer for the remaining shares upon completion of the transaction EssilorLuxottica intends to acquire full ownership in [...]
EssilorLuxottica : EssilorLuxottica se porte acquéreur de la participation de 76,72 % de HAL dans GrandVision et, une fois l’acquisition réalisée, lancera une offre publique obligatoire sur le solde du capital de GrandVision
31/07/2019
EssilorLuxottica se porte acquéreur de la participation de 76,72 % de HAL dans GrandVision et, une fois l’acquisition réalisée, lancera une offre publique obligatoire sur le solde du capital de GrandVision [...]

Pages